Get the Stockscreener App
424.53
0.02%
-1.0444
Vertex Pharmaceuticals Inc stock is traded at $424.53, with a volume of 966.82K.
It is down -0.02% in the last 24 hours and up +5.50% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$425.57
Open:
$428.48
24h Volume:
966.82K
Relative Volume:
0.54
Market Cap:
$108.84B
Revenue:
$11.39B
Net Income/Loss:
$3.64B
P/E Ratio:
30.34
EPS:
13.9904
Net Cash Flow:
$3.50B
1W Performance:
+1.27%
1M Performance:
+5.50%
6M Performance:
-15.10%
1Y Performance:
-9.68%
1-Day Range:
$418.60
$430.10
1-Week Range:
$415.00
$430.10
52-Week Range:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsJuly 2025 Macro Moves & Verified Entry Point Signals - newser.com
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryPortfolio Update Report & Safe Capital Investment Plans - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Tredje AP fonden - MarketBeat
Will Vertex Pharmaceuticals Incorporated benefit from macro trendsJuly 2025 Movers & Daily Volume Surge Signals - newser.com
Telos Capital Management Inc. Increases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Torray Investment Partners LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Welch & Forbes LLC - MarketBeat
South Dakota Investment Council Sells 10,780 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-11-03 04:36:10 - newser.com
Mission Wealth Management LP Reduces Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedMarket Activity Summary & Technical Pattern Based Buy Signals - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Arkadios Wealth Advisors - MarketBeat
Vertex Pharmaceuticals Incorporated’s volatility index tracking explainedEarnings Performance Report & Free AI Powered Buy and Sell Recommendations - newser.com
Is Vertex Pharmaceuticals Incorporated (VX1) stock a buy on weakness2025 Historical Comparison & Reliable Trade Execution Plans - newser.com
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performance2025 Retail Activity & Target Return Focused Stock Picks - newser.com
Vertex Pharmaceuticals (VRTX): Exploring Valuation After Promising Kidney Therapy Results and Growth in New Treatments - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Holdings Reduced by China Universal Asset Management Co. Ltd. - MarketBeat
Syverson Strege & Co Makes New $283,000 Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Keybank National Association OH Sells 1,523 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-11-02 03:14:13 - newser.com
Momentum divergence signals in Vertex Pharmaceuticals Incorporated chartTrade Volume Report & Capital Protection Trade Alerts - newser.com
Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect - The Globe and Mail
Vertex Pharmaceuticals Incorporated (VRTX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Vertex Pharmaceuticals Incorporated (VRTX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
VERTEX PHARMACEUTICALS Earnings Preview: Recent $VRTX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Top Biotech Stocks To Keep An Eye OnOctober 28th - MarketBeat
Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain. - MSN
Fisher Funds Management LTD Has $5.74 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Lockheed Martin Investment Management Co. Purchases 2,760 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Assetmark Inc. Acquires 7,094 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Journavx - AOL.com
How Vertex Pharmaceuticals Incorporated (VX1) stock compares with top peersShare Buyback & AI Powered Market Trend Analysis - newser.com
Vertex Pharmaceuticals Incorporated (VRTX.VI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by UNIVEST FINANCIAL Corp - MarketBeat
Strs Ohio Has $50.20 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Amalgamated Bank Purchases 2,005 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Spire Wealth Management Has $4.91 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Published on: 2025-10-31 03:53:17 - newser.com
Is Vertex Pharmaceuticals Incorporated stock supported by innovation pipelineWeekly Trade Recap & High Conviction Investment Ideas - newser.com
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potential - newser.com
Biopharma stocks regain ground in Q3 but still lag major indexes - BioWorld MedTech
Whalen Wealth Management Inc. Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Jennison Associates LLC Has $2.74 Billion Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Appoints New Leader in Europe to Advance Product Innovation and Strengthen Compliance - GlobeNewswire Inc.
How big funds are accumulating Vertex Pharmaceuticals Incorporated (VX1) stockJuly 2025 Reactions & Daily Profit Focused Screening - newser.com
Vertex Pharmaceuticals (VRTX) Stock Moves -1.23%: What You Should Know - Yahoo! Finance UK
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Published on: 2025-10-29 04:32:30 - newser.com
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):